The competent sentinel node: an association with an axillary presentation and an occult or a small primary invasive breast carcinoma by Mansfield, Lucy et al.
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
International Seminars in Surgical 
Oncology
Open Access Case report
The competent sentinel node: an association with an axillary 
presentation and an occult or a small primary invasive breast 
carcinoma
Lucy Mansfield*1, Haresh Devalia1, Nadeem Rehman1 and Kefah Mokbel1,2
Address: 1St. George's Hospital, London, UK and 2The Princess Grace, Hospital, London, UK
Email: Lucy Mansfield* - lucymansfield@hotmail.com; Haresh Devalia - hareshdevalia@doctors.org.uk; 
Nadeem Rehman - drnadeem74@hotmail.com; Kefah Mokbel - kefahmokbel@hotmail.com
* Corresponding author    
Abstract
The concept of the sentinel node describes a primary or sentinel lymph node (SLN), which exists
and through which tumour cells from a primary tumour in a particular location must first travel to
spread to a particular regional lymph node group. In this series we present three patients
presenting with a pathological axillary node associated with either an occult or very small primary
breast cancer. In each case the primary tumour was found to have metastasised to the palpable
node, however despite the significant enlargement of this node, no other axillary nodes were found
to be affected on axillary node clearance. This has led us to postulate that the SLN in some cases
contains unique characteristics that enable it to prevent further spread of the tumour up the
lymphatic chain. Hence the term the competent sentinel node.
Background
The concept of the sentinel node describes a primary or
sentinel lymph node (SLN), which exists and through
which tumour cells from a primary tumour in a particular
location must first travel to spread to a particular regional
lymph node group.
Recent studies have demonstrated that the sentinel node
biopsy (SNB), which utilizes a simple principle, is a relia-
ble and minimally invasive method for determining the
status of the regional lymph nodes in patients with clini-
cally node-negative breast cancer [1].
In this series we present three patients presenting with a
pathological axillary node associated with either an occult
or very small primary breast cancer. In each case the pri-
mary tumour was found to have metastasised to the pal-
pable node, however despite the significant enlargement
of this node, no other axillary nodes were found to be
affected on axillary node clearance. This has led us to pos-
tulate that the SLN in some cases contains unique charac-
teristics that enable it to prevent further spread of the
tumour up the lymphatic chain. Hence the term the "com-
petent sentinel node".
Case 1 (NL)
This 53-year-old lady presented with a pathological
lymph node in the left axilla measuring approximately 3
cm. No other abnormalities were noted. Mammography,
ultrasound examination and MRI scanning confirmed the
presence of a pathological lymph node with no evidence
of a breast primary lesion (fig. 1). In addition a CT scan of
the thorax again showed the solitary axillary lymph node
however no other abnormalities. A fine needle aspiration
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cytology (FNAC) of this node was reported as metastatic
breast carcinoma. (ER, PgR, CerbB2, positive). It was
decided at this point to proceed to a level I-III axillary
lymph node dissection. Pathological examination
revealed only 1/14 axillary nodes showing metastatic car-
cinoma consistent with a breast primary. This node meas-
ured 38 mm in greatest dimension (ER 8/8, PgR 8/8,
CerbB2 2+). There was no extracapsular spread and all
adjacent fatty tissue showed normal duct-lobular breast
units. The patient was subsequently treated with chemo-
therapy, breast irradiation and endocrine therapy.
Case 2 (SM)
This 33-year-old lady presented with a pathological
lymph node in the right axilla measuring approximately 3
cm. No other abnormalities were noted. Mammography,
ultrasound examination and MRI scanning confirmed the
presence of a pathological lymph node (30 mm MRI size).
The USS showed an indeterminate area in the lateral
aspect of the right breast which was confirmed to be the
primary lesion on core biopsy. An FNAC of the lymph
node was reported as metastatic breast carcinoma. It was
decided at this point to proceed to a level I-III axillary
lymph node dissection combined with skin-sparing mas-
tectomy and immediate reconstruction. Pathological
examination revealed a 4 mm a primary breast carcinoma
(grade 3 infiltrating ductal, negative for ER, PgR and Her-
2) and only 1/21 axillary nodes showed metastatic carci-
noma. There was only very scanty extracapsular spread.
The patient was subsequently treated with chemotherapy.
Case 3 (JW)
This 48-year-old lady presented with a pathological
lymph node in the right axilla measuring approximately 3
cm. No other abnormalities were noted. Mammography,
ultrasound examination and MRI scanning confirmed the
presence of a pathological lymph node (35 mm MRI size).
No primary lesion was identifies. An FNAC of the lymph
node was reported as metastatic breast carcinoma. It was
decided at this point to proceed to a level I-III axillary
lymph node dissection. Pathological examination
revealed only 1/10 axillary nodes showing metastatic car-
cinoma consistent with a breast primary. This node meas-
ured 35 × 25 × 20 mm. E-cadherin was positive consistent
with a ductal carcinoma of the breast. The HER-2 FISH
result revealed a ratio of 0.89. Her treatment was com-
pleted with chemotherapy and radiotherapy to the breast.
Two years later she continues to take tamoxifen and there
has been no evidence of recurrence.
Discussion
The history of breast cancer management during the last
few decades has been one of decreasing invasiveness in
order to try and achieve a much lower level of morbidity.
To help reach this improved level of treatment the concept
of the SLN was utilized.
This concept describes a primary or sentinel lymph node
(or nodes), which exists and through which tumour cells
from a primary tumour in a particular location must first
travel to spread to a particular regional lymph node
group. These sentinel nodes are therefore the nodes most
likely to harbor tumour cells if the cancer has indeed
entered the lymphatics. A tracer substance (a radioactive
isotope and blue dye) injected into the breast provides a
roadmap leading to the SLN(s).
The SLN concept was initially introduced by Cabanas in
1977 [2]. He applied it to the management of penile can-
cer. The technique was popularized in the 1980s and early
1990s in the management of melanoma by Morton et al
[3]. They used the injection of isosulfan blue dye to allow
visualisation as it flowed through, and stained lymphatic
channels and nodes, enabling identification, excision and
assessment of blue-stained nodes. In the early 1990s the
SLN concept was applied to the management of breast
Title: Mammogram from case 1 Figure 1
Title: Mammogram from case 1. Data description: Mammo-
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cancer patients. These initial efforts followed the progress
made in the management of melanoma, predominantly
with the use of both radiotracer and blue-dye techniques
to help identify the sentinel node. The SNB has now
become the gold standard of assessing the invasion of
tumour into the lymphatics in patients with clinically
node-negative invasive breast cancer with a much lower
operative morbidity than the previously routine axillary
nodal dissections [1,4].
It is well recognised that intravasation of tumour cells into
the vasculature and/or lymphatics is a key stage in the
metastatic process, and the technique of sentinel node
biopsy has provided confirmation of the orderly anatomic
progression of tumour cells from the primary site to the
regional lymph nodes through lymphatic capillaries and
trunks [5]. There remains very little understanding in
regards to the mechanisms involved in these events. Less
is known about the methods of lymphatic intravasation in
comparison to vascular invasion. However the process of
lymphangiogenesis is thought to be similar to the well-
known mechanism of angiogenesis. Molecular research
techniques have suggested that likely factors involved
include tumour-secreted cytokines such as vascular
endothelial growth factors, tumour cell expression of spe-
cific chemokine receptors, adhesion molecules and
integrins [5,6]. The directional movement towards lym-
phatics and lymph nodes appears to follow a chemokine
environment [5].
From our case series we have developed the theory of the
"competent sentinel node". Interestingly, all the cases had
axillary presentation and were associated with either an
occult or very small primary tumour. Examination of the
nodes invaded with tumour cells, revealed them all to be
of a significant size without any significant extra-capsular
spread. More importantly in each axillary nodal clearance
no other nodes were found to be affected, despite the sig-
nificant size and tumour load within the affected node
which is by definition is the true SLN. A study by Wada et
al supports our findings, suggesting that a small primary
tumour size is less likely to be associated with involve-
ment of non-SLNs [7].
This raises the question in regards to the competency of
the sentinel node. Our concept of competent SLN is also
consistent with the observation that the SLN is the only
node involved in approximately two thirds of node posi-
tive patients [1,4]. There appears to be some inherent abil-
ity within the SLN in such cases that prevents spread of the
tumour further up the lymphatic chain and this could be
indicative of good prognosis. The sentinel node appears
to provide a favorable molecular micro-environment
which allows the tumour cells to survive and proliferate.
Further studies and research needs to be performed in
order to help examine what determines this competence,
if indeed it does exist. The anatomical efferent lymphatic
pathway, tumour pathology and local biological factors
within the lymph nodes involved may help provide an
answer to help explain the ability of the sentinel node to
contain further tumour spread, i.e. its competency. This is
obviously an area that requires much more research in
order to create a much greater understanding in regards to
the properties of the sentinel node and the exact mecha-
nisms behind tumour spread.
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